5α还原酶抑制剂与α受体阻滞剂对前列腺癌发病及死亡率的影响
该回顾性20年队列研究纳入加拿大萨斯喀彻温省40-89岁BPH男性,比较5ARI使用者、α受体阻滞剂使用者与非使用者的前列腺癌发病、严重程度及死亡率。结果显示5ARI使用者前列腺癌诊断风险约低40%,但两类药物使用者高级别(Gleason 8-10)前列腺癌风险约高30%,转移和死亡风险无显著差异。
要点
- 5ARI使用者前列腺癌诊断风险较非使用者及α受体阻滞剂使用者约低40%。
- 5ARI与α受体阻滞剂使用者高级别前列腺癌风险均约增加30%。
- 两类药物均未显著增加转移性前列腺癌或前列腺癌死亡风险。
核心结论
- 5ARI使用与前列腺癌诊断风险降低相关,但5ARI和α受体阻滞剂使用者高级别前列腺癌风险均升高,未转化为前列腺癌死亡风险升高。
研究设计与样本
- 回顾性20年队列研究,纳入1995-2014年加拿大萨斯喀彻温省40-89岁有BPH编码医疗索赔的男性。
主要发现
- 5ARI使用者前列腺癌诊断率5.8%,非使用者11.0%,α受体阻滞剂使用者11.4%。
- α受体阻滞剂使用者较非使用者前列腺癌诊断风险低11%。
- 转移性前列腺癌调整HR:5ARI 1.12,α受体阻滞剂1.13,均P>0.05。
- 前列腺癌死亡调整HR:5ARI 1.11,α受体阻滞剂1.18,均P>0.05。
- Gleason 8-10癌调整HR:5ARI 1.37(95%CI 1.03-1.82,P=0.03),α受体阻滞剂1.28(95%CI 1.03-1.59,P=0.02)。
临床怎么用
- 对BPH患者使用5ARI或α受体阻滞剂时,应知晓高级别前列腺癌风险可能升高,需结合PSA和活检策略审慎评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the use of 5α-reductase inhibitors (5ARIs) and α-blockers among men with benign prostatic hyperplasia (BPH) in relation to prostate cancer (PCa) incidence, severity and mortality. PATIENTS AND METHODS: A retrospective 20-year cohort study in men residing in Saskatchewan, aged 40-89 years, with a BPH-coded medical claim between 1995 and 2014, was conducted. Cox proportional hazards regression was used to compare incidence of PCa diagnosis, metastatic PCa, Gleason score 8-10 PCa, and PCa mortality among 5ARI users (n = 4 571), α-blocker users (n = 7 764) and non-users (n = 11 677). RESULTS: In comparison with both non-users and α-blocker users, 5ARI users had a ~40% lower risk of a PCa diagnosis (11.0% and 11.4% vs 5.8%, respectively), and α-blocker users had an 11% lower risk of a PCa diagnosis compared with non-users. Overall, the incidence of metastatic PCa and PCa mortality was not significantly different among 5ARI or α-blocker users compared with non-users (adjusted hazard ratios [HR] of metastatic PCa: 1.12 and 1.13, respectively, and PCa mortality: 1.11 and 1.18, respectively, P > 0.05 for both drugs), but both 5ARI and a-blocker users had ~30% higher risk of Gleason score 8-10 cancer, adjusted HR 1.37, 95% confidence interval [CI] 1.03-1.82, P = 0.03, and adjusted HR 1.28, 95% CI 1.03-1.59, P = 0.02, respectively compared with non-users. CONCLUSION: The use of 5ARIs was associated with lower risk of PCa diagnosis, regardless of comparison group. Risk of high grade PCa was higher among both 5ARI users and α-blocker users compared with non-users; however, this did not translate into higher risk of PCa mortality.
引用
- Van Rompay MI, Curtis Nickel J, Ranganathan G, et al. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality. BJU Int. 2018. PMID: 30216624. doi:10.1111/bju.14534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。